TGFB1 and neoplasm: Four mice that had rejected a CT26 tumor after treatment with a combination of anti-PD-1 WT and anti-GARP:TGF-β1 WT were injected 47 days after the last mAb administration with live CT26 cells in the right flank, and live RENCA or EMT6 syngeneic tumor cells in the left flank.